PubMed日本語 - 限局性強皮症のインターロイキン-17Aとインターロイキン-23。―QLifePro医療翻訳医療翻訳 QLifePro



Interleukin-17A and interleukin-23 in morphea.

Published date 2012 Dec 19


Interleukin-17A and interleukin-23 in morphea.


Published date



Aleksandra Dańczak-Pazdrowska, Michał Kowalczyk, Beata Szramka-Pawlak, Justyna Gornowicz-Porowska, Aleksandra Szewczyk, Wojciech Silny, Anna Olewicz-Gawlik, Marta Molińska-Glura, Ryszard Zaba, Paweł Hrycaj


Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.


INTRODUCTION: Morphea is a disease included in the group of scleroderma type autoimmune diseases. Interleukin (IL)-17A may play a role at every stage of its pathogenesis. The study aimed at evaluation of IL-17A and IL-23 (as the main cytokine which is supposed to stimulate and maintain synthesis of IL-17) in pathogenesis of morphea.


MATERIAL AND METHODS: The studies were performed on 41 blood samples from patients with morphea. Skin was sampled from 29 patients. The evaluation included: (1) expression of IL-17A and IL-23 genes in peripheral blood mononuclear cells (PBMC) using real-time polymerase chain reaction (PCR), (2) plasma concentrations of IL-17A and IL-23 using ELISA, (3) expression of IL-17A and IL-23 genes in skin using real-time PCR.


RESULTS: The results of gene expression are expressed as median number of copies per million copies of GAPDH. Higher expression of IL-17A has been demonstrated in PBMC of morphea vs. control group (2630 and 1906 respectively; p = 0.004), accompanied by absence of significant differences in its plasma concentration (10 pg/ml in both groups) and by lowered expression in affected skin (9119 and 19113 respectively; p = 0.036). The results failed to demonstrate elevated IL-23 plasma concentration in morphea vs. control group (5 pg/ml and 6 pg/ml respectively; p = 0.335) or its increased expression in the skin (292 vs. 427; p = 0.383), although we noted its increased expression in PBMC (4419 vs. 808; p < 0.001).


CONCLUSIONS: BASED ON THE OBSERVED CORRELATIONS WE SUGGEST THAT: (1) IL-17A does not represent a factor which promotes tissue injury in morphea, (2) IL-23 may playa role in pathogenesis of morphea.


評価は以下を含んだ: (1) リアルタイム・ポリメラーゼ連鎖反応(PCR)、(2) IL-17Aの血漿濃度とELISAを用いたIL-23、(3)リアルタイムPCRを使用している皮膚のIL-17AとIL-23遺伝子の発現を使用している末梢血単核細胞(PBMC)のIL-17AとIL-23遺伝子の発現。
IL-17Aのより高度な表示は、限局性強皮症対対照群のPBMCで示された(それぞれ2630と1906;p = 0.004)、その血漿濃度(両群における10pg/ml)の有意差の欠如によって、そして、影響を受けた皮膚の降ろされた表現によって付随する(それぞれ9119と19113;p = 0.036)。
結果は、限局性強皮症対対照群で高いIL-23血漿濃度を示すのに失敗した(それぞれ5pg/mlと6pg/ml;p = 0.335)または皮膚のそのさらなる表現(292対427;p = 0.383)、我々がPBMCのそのさらなる表現に注意したにもかかわらず、(4419対808;p < 0.001)。
結論:我々が提案する観察された相関に関して基づく以下 (1) IL-17Aは、限局性強皮症((2) IL-23限局性強皮症の病因でのプラヤ役割)で組織損傷を促進する因子を表さない。

460万語の専門辞書を備えた医療者専用翻訳サービス QLifePro医療翻訳